Treatment of ALK-positive non-small cell lung cancer

Archives of Pathology and Laboratory Medicine

Volumn 136, Issue 10, 2012, Pages 1201-1204

  Bang, Yung Jue ^a  

^a Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ANTINEOPLASTIC AGENT; CRIZOTINIB; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ARTICLE; GENE REARRANGEMENT; GENETICS; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC);

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; GENE REARRANGEMENT; HUMANS; LUNG NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84868312005     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2012-0246-RA     Document Type: Conference Paper

References (30)

1. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 2011;12(2):175-180.
2. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153): 561-566.
3. Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007;131(6):1190- 1203.
4. Bang YJ. The potential for crizotinib in non-small cell lung cancer: a perspective review. Ther Adv Med Oncol. 2011;3(6):279-291.
5. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363(18):1693- 1703.
6. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009;27(26):4247-4253.
7. Rodig SJ, Mino-Kenudson M, Dacic S, et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res. 2009;15(16):5216-5223.
8. Mino-Kenudson M, Chirieac LR, Law K, et al. A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res. 2010;16(5):1561-1571.
9. Paik JH, Choi CM, Kim H. Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma [published online ahead of print November 28, 2011]. Lung Cancer. doi:10.1016/j.lungcan.2011.11.008.
10. Hirsch FR, Wynes MW, Gandara DR, Bunn PA Jr. The tissue is the issue: personalized medicine for non-small cell lung cancer. Clin Cancer Res. 2010; 16(20):4909-4911.
11. Christensen JG, Zou HY, Arango ME, et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther. 2007; 6(12, pt 1):3314-3322.
12. Zou HY, Li Q, Lee JH, et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 2007;67(9):4408-4417.
13. Bang Y, Kwak EL, Shaw AT, et al. Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC) [abstract 3]. J Clin Oncol. 2010;28(suppl):18s.
14. Camidge DR, Bang Y, Kwak EL, et al. Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC) [abstract 2501]. J Clin Oncol. 2011;29(suppl):165s.
15. Crinò L, Kim D-W, Riely G, et al. Initial phase 2 results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005 [abstract 7514]. J Clin Oncol. 2011;29(suppl):479s.
16. Xalkori prescribing information. http://www.accessdata.fda.gov/ drugsatfda-docs/label/2011/202570s000lbl.pdf. Accessed October 7, 2011
17. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22(9):1589-1597.
18. Shepherd FA, Rodrigues PJ, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353(2):123-132.
19. Camidge DR, Theodoro M, Maxson DA, et al. Correlations between the percentage of tumor cells showing an ALK (anaplastic lymphoma kinase) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive nonsmall cell lung cancer [published online ahead of print January 26, 2012]. Cancer. doi:10.1002/cncr. 27411.
20. Ou SHI, Salgia R, Clark J. Comparison of crizotinib (PF-02341066) pharmacokinetics between Asian and non-Asian patients with advanced malignancies. J Thorac Oncol. 2010;5(suppl. 5):S382.
21. Riely G, Kim D-W, Crinò L, et al. Phase 2 data for crizotinib (PF-02341066) in ALK-positive advanced non-small cell lung cancer (NSCLC): PROFILE 1005 [abstract 1618]. J Thorac Oncol. 2011;6(suppl 2):411s.
22. Shaw AT, Yeap BY, Solomon BJ, et al. Effect of crizotinib on overall survival in advanced NSCLC harboring anaplastic lymphoma kinase gene rearrangement: a retrospective analysis. Lancet Oncol. 2011;11:1004-1012.
23. Solomon B, Chiappori A, Lamb A, et al. Preliminary characterization of visual events reported by patients receiving crizotinib for the treatment of advanced ALK-positive non-small cell lung cancer. Poster presented at: European Multidisciplinary Cancer Congress; September 23-27, 2011; Stockholm, Sweden. Abstract 3030.
24. Blackhall FH, Petersen JA, Wilner K, et al. PROFILE 1005: preliminary patient-reported outcomes (PROs) from an ongoing phase 2 study of crizotinib (PF-02341066) in anaplastic lymphoma kinase (ALK)-positive advanced nonsmall cell lung cancer (NSCLC). Oral presentation at: 14th World Conference on Lung Cancer (WCLC); July 3-7, 2011; Amsterdam, The Netherlands.
25. Kim DW, Blackhall F, Soria JC, et al. A global phase 2 study including efficacy, safety and patient-reported outcomes (PROs) with crizotinib in patients (Pts) with ALK-positive non-small cell lung cancer (NSCLC) [abstract]. Eur J Cancer. 2011;47(suppl):S617.
26. Zhang S, Wang F, Keats J, et al. Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen. Chem Biol Drug Des. 2011;78(6):999-1005.
27. Sasaki T, Koivunen J, Ogino A, et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res. 2011; 71(18):6051-6060.
28. Choi YL, Soda M, Yamashita Y, et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med. 2010;363(18):1734-1739.
29. Katayama R, Shaw AT, Khan TM, et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med. 2012;4(120):120ra17.
30. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer (v.2.2012). Fort Washington, PA: NCCN; 2012.